Neurocrine Biosciences announced the FDA has approved INGREZZA SPRINKLE, or valbenazine, capsules, a new oral granules formulation of INGREZZA, or valbenazine, capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease. INGREZZA SPRINKLE provides an alternative administration option for those who experience dysphagia or have difficulty swallowing. Like the original formulation of INGREZZA capsules, INGREZZA SPRINKLE offers simple dosing that’s always one capsule, once daily with no complex titration. INGREZZA is the only selective vesicular monoamine transporter 2 inhibitor that offers three effective dosages that can be adjusted by the healthcare provider based on patient response and tolerability. INGREZZA SPRINKLE offers the same dosage strengths, and the contents of the capsules can be easily sprinkled on soft food for oral administration.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- NBIX Upcoming Earnings Report: What to Expect?
- Tesla, Airbnb upgraded: Wall Street’s top analyst calls
- Wells Fargo upgrades Neurocrine with pipeline ‘turning a corner’
- Neurocrine upgraded to Overweight from Equal Weight at Wells Fargo
- Neurocrine NBI-1065845 results ‘look potentially promising,’ says RBC Capital